PharMEDium Recalls Sterile Injectable Drugs Contaminated with Glass Particulate Matter
PharMEDium Services is recalling 650 bags of sterile injectable drugs containing hydromorphone and bupivacaine due to the presence of glass particulate matter.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the presence of glass particulate matter in sterile injectable drugs poses a significant risk of injury, meeting the criteria for a Severe rating.
Plain-English summary
PharMEDium Services, LLC is recalling 650 bags of 8 mcg/mL HYDROmorphone HCl and 0.05% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride. The product is compounded in 250 mL Hospira LifeCare Bags and is distributed nationwide. The recall involves specific lots with expiration dates ranging from May 9, 2016, to July 6, 2016.
The recall was initiated because the active pharmaceutical ingredient (API) used to produce these sterile injectable drugs was contaminated with glass particulate matter. The presence of particulate matter in sterile injectable products poses a risk to patient safety.
Healthcare providers and patients who have received or possess these specific lots should stop using the product and contact PharMEDium Services or their local FDA office for further instructions. The affected lots are identified by specific lot numbers and expiration dates listed in the official recall notice.
The recalled product
- Product
- 8 mcg/mL HYDROmorphone HCl and 0.05% Bupivacaine HCl (Preservative Free) in 0.9% Sodium Chloride, 250 mL in 250 mL Hospira LifeCare Bag, Service Code 2H9310, Rx Only, Compounded by PharMEDium Services, LLC, Memphis, TN 36141, NDC 61553-310-50
- Manufacturer
- Pharmedium Services, LLC
- Category
- Drug — Sterile Injectable
- Affected units
- 650
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot Number 160390094M
- Exp. Date 5/9/2016
- Lot Number 160450111M
- Exp. Date 5/15/2016
- Lot Number 160520101M
- Exp. Date 5/22/2016
- Lot Number 160550109M
- Exp. Date 5/25/2016
- Lot Number 160610124M
- Exp. Date 5/31/2016
- Lot Number 160620115M
- Exp. Date 6/1/2016
- Lot Number 160670036M
- Exp. Date 6/5/2016
- Lot Number 160680038M
- Exp. Date 6/7/2016
- Lot Number 160690110M
- Lot Number 160740117M
- Exp. Date 6/12/2016
- Lot Number 160760109M
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 75 recalled by Pharmedium Services, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 75 products in this recall →Related recalls
Same manufacturer · Pharmedium Services, LLC
See all →- SeverePharMEDium Recalls ePHEDrine Sulfate Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls nICARdipine HCl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Rocuronium Bromide Syringes Due to Sterility Assurance Issues
FDA (Drugs) · 2020-04-15
- SeverePharMEDium Recalls Fentanyl Citrate Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2020-04-15
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26